One of Novo Nordisk's next-generation obesity shots to follow up on its success with Wegovy helped patients lose 22% of their ...

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here ...

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% ...

Danish healthcare company Novo Nordisk A/S (NVO) announced topline results from a phase 1b/2a clinical trial with amycretin, a ...

A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...

Novo Nordisk's amycretin trial results highlight significant weight loss in adults with obesity, with further clinical development planned.

Novo Nordisk's experimental obesity drug, amycretin, displayed impressive results, causing a 22% weight loss in participants over 36 weeks. The news boosted Novo’s shares and highlights its potential ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly ...